Viking Therapeutics starts oral trial as Truist targets Viking Therapeutics stock at USD 87

Viking Therapeutics (ISIN US92686J1060) announced initiation of an oral VK2735 maintenance dosing trial for patients with obesity on October 6, 2026. Viking Therapeutics said the study will evaluate oral maintenance regimens after initial weight loss, while monthly and every-other-week subcutaneous regimens will also be evaluated. Truist Securities raised its target from USD 83.00 to USD 87.00 on September 23, 2026, according to MarketBeat.

Oral dosing broadens VK2735 plans

The new trial adds a maintenance strategy to Viking's obesity program rather than replacing the existing injectable approach. That distinction matters because long-term weight management can require continued dosing after initial weight reduction.

Viking's corporate profile identifies VK2735 as a dual glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptor agonist. The company is also developing VK2809 for metabolic and liver disorders, VK3019 for obesity and VK0214 for X-linked adrenoleukodystrophy.

Target increase meets clinical execution risk

Truist's USD 87.00 target was USD 4.00 above its previous USD 83.00 target, a 4.82 percent increase. The change contrasts with the clinical uncertainty that accompanies a development-stage biotechnology company, where trial outcomes and later regulatory decisions remain central valuation variables.

On October 6, 2026, Viking Therapeutics had a market capitalization of USD 3.3 billion, a 52-week range of USD 25.77 to USD 43.15 and trading volume of 7,100,854 shares. The range places the company in a wide valuation corridor as investors weigh VK2735's development potential against ongoing research spending.

Prior close sets the euro reference

The prior close at Lang & Schwarz was EUR 25.33 on October 5, 2026. The further course of trading is shown by the continuously updated real-time quote of Viking Therapeutics stock.

More news and analyses on Viking Therapeutics stock